A provider status bill has been introduced in Congress with bipartisan support.

A big moment for pharmacy.

Learn about the Provider Status bill

Featured Education

Upcoming Events

Practice Resources

Tools and resources to support your practice

image-7 image-8

Latest from APhA

View CEO Blog

Pharmacy needs payment reform to thrive. We’re fighting for it on two fronts.

This week marked the end of my first year as CEO of APhA. From the moment I stepped into APhA headquarters, the World Home of Pharmacy, I was humbled by this amazing organization and all that APhA has accomplished in its 169-year history. I take very seriously the responsibility that comes with leading this storied institution. I've never doubted that the members of this profession had the mettle to look a dragon in the eye and slay it, but this year I've watched that talent and fortitude in action, and it's perhaps the most unforgettable sight of my life. The honor of supporting and advocating for our pharmacy heroes has changed my life forever and together, we’re changing the world for good. 


APhA Joins NCPA Suit Against Backdoor Pharmacy Fees

Litigation aims to overturn HHS rules allowing pharmacy benefit managers to wring fees out of pharmacies and consumers long after the point of sale

WASHINGTON, DC—The American Pharmacists Association (APhA) today joined the National Community Pharmacists Association (NCPA) as an equal partner in a federal lawsuit challenging a confusing scheme of retroactive fees imposed on pharmacies and, indirectly, their patients.


Pharmacy news

View all news

ISMP updates COVID-19 vaccine errors

The Institute for Safe Medication Practices (ISMP) continues to track the errors that have been reported from the currently authorized COVID-19 vaccines.

FDA approves higher dosage of naloxone nasal spray

On April 30, FDA announced the approval of a higher dosage of naloxone hydrochloride nasal spray (Kloxxado—Hikma Pharmaceuticals) to treat opioid overdose. The newly approved product delivers 8 mg of naloxone into the nasal cavity, compared with previously approved 2- and 4-mg naloxone nasal spray products.